332 related articles for article (PubMed ID: 16935228)
1. Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?
Wolsey DH; Larson SA; Creel D; Hoffman R
J AAPOS; 2006 Aug; 10(4):307-11. PubMed ID: 16935228
[TBL] [Abstract][Full Text] [Related]
2. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas.
Kelly JP; Weiss AH
J AAPOS; 2006 Aug; 10(4):298-306. PubMed ID: 16935227
[TBL] [Abstract][Full Text] [Related]
4. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
5. [Long-term outcome of gliomas of the visual pathway in type 1 neurofibromatosis].
Schröder S; Baumann-Schröder U; Hazim W; Haase W; Mautner VF
Klin Monbl Augenheilkd; 1999 Dec; 215(6):349-54. PubMed ID: 10637799
[TBL] [Abstract][Full Text] [Related]
6. VEP testing and visual pathway gliomas: not quite ready for prime time.
Siatkowski RM
J AAPOS; 2006 Aug; 10(4):293-5. PubMed ID: 16935225
[No Abstract] [Full Text] [Related]
7. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis Type 1: Description of a Novel Diagnostic Scoring System in Pediatric Optic Nerve Glioma.
Eid H; Crevier-Sorbo G; Aldraihem A; Menegotto F; Wilson N
AJR Am J Roentgenol; 2019 Apr; 212(4):892-898. PubMed ID: 30741560
[TBL] [Abstract][Full Text] [Related]
10. Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit.
Pilling RF; Lloyd IC; Huson S
Eye (Lond); 2010 Oct; 24(10):1603-5. PubMed ID: 20689568
[TBL] [Abstract][Full Text] [Related]
11. The role of visual electrodiagnostics in management of children with neurofibromatosis type 1.
Tekavčič Pompe M; Pečarič Meglič N; Šuštar Habjan M
Doc Ophthalmol; 2023 Apr; 146(2):121-136. PubMed ID: 36652041
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
Kelly JP; Leary S; Khanna P; Weiss AH
Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
[TBL] [Abstract][Full Text] [Related]
13. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
14. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.
Dotto PF; Berezovsky A; Cappellano AM; da Silva NS; Sacai PY; Silva FAB; Fernandes AG; Rocha DM; Salomão SR
Doc Ophthalmol; 2018 Jun; 136(3):177-189. PubMed ID: 29766345
[TBL] [Abstract][Full Text] [Related]
15. Anisometropia in children with neurofibromatosis type 1 and unilateral optic nerve glioma.
Dotan G; Keren S; Stolovitch C; Toledano-Alhadef H; Kesler A
J AAPOS; 2014 Jun; 18(3):255-7. PubMed ID: 24924279
[TBL] [Abstract][Full Text] [Related]
16. Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.
Van Mierlo C; Spileers W; Legius E; Casteels I; Cassiman C
Doc Ophthalmol; 2013 Dec; 127(3):177-90. PubMed ID: 23884797
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm.
Caen S; Cassiman C; Legius E; Casteels I
Eur J Paediatr Neurol; 2015 Jul; 19(4):415-22. PubMed ID: 25797697
[TBL] [Abstract][Full Text] [Related]
18. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.
Balcer LJ; Liu GT; Heller G; Bilaniuk L; Volpe NJ; Galetta SL; Molloy PT; Phillips PC; Janss AJ; Vaughn S; Maguire MG
Am J Ophthalmol; 2001 Apr; 131(4):442-5. PubMed ID: 11292406
[TBL] [Abstract][Full Text] [Related]
19. A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas.
Trisciuzzi MT; Riccardi R; Piccardi M; Iarossi G; Buzzonetti L; Dickmann A; Colosimo C; Ruggiero A; Di Rocco C; Falsini B
Clin Neurophysiol; 2004 Jan; 115(1):217-26. PubMed ID: 14706491
[TBL] [Abstract][Full Text] [Related]
20. Neuroophthalmological management of optic pathway gliomas.
Lee AG
Neurosurg Focus; 2007; 23(5):E1. PubMed ID: 18004957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
